Why carry out this study?
|
Mesothelin (MSLN) is overexpressed in several tumors including ovarian cancer and is the target of current trials. |
There is limited and conflicting data on MSLN prognostic impact in ovarian cancer. |
This study evaluated MSLN expression in patients with high-grade serous ovarian cancer and its association level with clinical parameters. |
What was learned from the study?
|
Our data showed that MSLN expression did not correlate with clinical outcome (OS or PFS), and there was a positive correlation between MSLN expression in the metastatic site and CD11c expression in total tumor area and perivascular area in the primary tumor. |
These results confirms that MSLN expression does not correlate with clinical outcome impact. |
The correlation between MSLN and CD11c+ cells should be further explored. |
Digital Features
Introduction
Methods
Patients and Methods
Statistical Analysis
Results
Patients
Characteristic | Patient cohort N = 126 |
---|---|
Median age at diagnosis, years (range) | 64 (36.5–84.2) |
Diagnosis | |
Ovarian cancer | 88 (69.8%) |
Fallopian tube cancer | 13 (10.3%) |
Peritoneal cancer | 22 (17.5%) |
Undesignated site | 3 (2.4%) |
Missing | 0 |
FIGO stage | |
IIC | 2 (1.6%) |
IIIA | 1 (0.8%) |
IIIB | 6 (4.0%) |
IIIC | 92 (73.0%) |
IV | 25 (19.8%) |
Missing | 0 |
Type of surgery | |
Primary surgery | 99 (78.6%) |
Delayed primary/interval | 18 (14.3%) |
No surgery | 9 (7.1%) |
Missing | 0 |
Macroscopic residual disease after surgery | |
Absent | 33 (28.2%) |
Present | 84 (71.8%) |
Missing | 0 |
Chemotherapy first line | |
Platinum based | 116 (92.0%) |
No platinum | 1 (0.8%) |
No chemo | 8 (6.3%) |
Missing | 1 (0.8%) |
Response at EOT | |
CR | 69 (59.0%) |
PR | 26 (22.2%) |
SD | 3 (2.6%) |
PD | 16 (13.7%) |
Missing | 3 (2.6%) |
Survival | |
Alive with no evidence of disease | 4 (3.2%) |
Alive with evidence of disease | 5 (4.0%) |
Dead from ovarian cancer | 111 (88.1%) |
Dead from other causes | 3 (2.4%) |
Lost at follow-up | 3 (2.4%) |
Median follow-up | 36.4 months (0.4–171.9) |
Missing | 0 |
Time from EOT to recurrence/progression | |
≥ 6 months (platinum sensitive) | 70 (60.3%) |
< 6 months (platinum resistant) | 46 (39.7%) |
Missing | 0 |
MSLN Expression in Adnexa and Metastatic Site
OS and PFS
MSLN Expression Related to Immunomarkers
CD11c | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
PVA1 | PVA2 | tot. tum | epith | stroma | tot. tum | PVA1 | stroma | epith | ||
Adnexal site | Metastatic sitea | |||||||||
MSLN adn | r | 0.108 | 0.060 | − 0.008 | 0.056 | 0.058 | 0.074 | 0.036 | − 0.048 | − 0.113 |
p | 0.434 | 0.662 | 0.954 | 0.686 | 0.676 | 0.54 | 0.762 | 0.659 | 0.302 | |
MSLN met | r | 0.344* | 0.246 | 0.276* | 0.166 | 0.170 | − 0.123 | − 0.051 | 0.008 | 0.046 |
p | 0.011 | 0.072 | 0.043 | 0.229 | 0.218 | 0.303 | 0.67 | 0.938 | 0.674 |
CD80 | CD163 | CD8 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PVA1 | PVA2 | tot. tum | stroma | epith | PVA1 | PVA2 | tot. tum | stroma | epith | epith | stroma | stroma 2–3 | |
MSLN adn | − 0.009 | 0.012 | − 0.131 | − 0.121 | − 0.030 | − 0.080 | − 0.130 | − 0.136 | − 0.109 | 0.008 | 0.160 | 0.050 | 0.100 |
0.947 | 0.927 | 0.343 | 0.382 | 0.826 | 0.563 | 0.347 | 0.324 | 0.430 | 0.952 | 0.247 | 0.719 | 0.471 | |
MSLN met | 0.188 | 0.103 | 0.006 | − 0.043 | 0.049 | 0.055 | 0.006 | − 0.033 | − 0.002 | 0.112 | 0.095 | 0.078 | 0.099 |
0.173 | 0.459 | 0.962 | 0.755 | 0.725 | 0.688 | 0.962 | 0.811 | 0.987 | 0.417 | 0.494 | 0.571 | 0.476 |